CRSP Stock Analysis: Crispr Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.371m USD | 12M Return: 15.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 84.9M
Qual. Beats: 0
Rev. Trend: -87.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 9.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CRISPR Therapeutics AG is a clinical-stage gene editing company that uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines for serious human diseases. The company is headquartered in Zug, Switzerland, was incorporated in 2013, and trades on the NASDAQ under the ticker CRSP. Its pipeline spans hemoglobinopathies, CAR T cell therapies, in vivo gene editing, and type 1 diabetes.
The companys lead product is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy approved in collaboration with partner Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia and severe sickle cell disease. Additional programs include CTX112 (CD19) and CTX131 (CD70) CAR T candidates for oncology and autoimmune indications, in vivo candidates CTX310 and CTX320 targeting cardiovascular disease, and CTX211, an allogeneic stem cell-derived therapy for type 1 diabetes. Like many clinical-stage biotechnology companies, CRISPR Therapeutics relies on strategic partnerships and capital markets to fund lengthy drug development cycles before products reach commercialization.
- CASGEVY commercial uptake with Vertex drives revenue
- In vivo gene editing pipeline advances for cardiovascular diseases
- Cash burn and equity dilution pressure shareholders amid development
| Net Income: -568.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA -4.74 > 1.0 |
| NWC/Revenue: 56.4k% < 20% (prev 4.73k%; Δ 51.6k% < -1%) |
| CFO/TA -0.15 > 3% & CFO -400.0m > Net Income -568.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (96.1m) vs 12m ago 11.77% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.17% > 50% (prev 1.71%; Δ -1.54% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.85 (Total Current Assets 2.45b - Total Current Liabilities 136.3m) / Total Assets 2.73b |
| B: -0.76 (Retained Earnings -2.07b / Total Assets 2.73b) |
| C: -0.23 (EBIT TTM -565.2m / Avg Total Assets 2.45b) |
| D: 1.99 (Book Value of Equity 1.81b / Total Liabilities 911.3m) |
| Altman-Z'' = 3.63 = AA |
As of July 05, 2026, the stock is trading at USD 60.08 with a total of 2,931,700 shares traded. Over the past week, the price has changed by +11.30%, over one month by +15.36%, over three months by +22.24% and over the past year by +15.16%.
Current recommended Stop Loss: 56.60 (which is 5.8% or 1.2 ATR below the current price).
Crispr Therapeutics has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy CRSP.
- StrongBuy: 12
- Buy: 5
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 83.5 | 39% |
P/E Forward = 23.3645
P/S = 1309.1212
P/B = 2.9601
P/EG = -0.2142
Revenue TTM = 4.10m USD
EBIT TTM = -565.2m USD
EBITDA TTM = -546.2m USD
Long Term Debt = 585.5m USD (from longTermDebt, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 989.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 202.2m
Net Debt = -1.45b USD (calculated: Debt 989.8m - CCE 2.44b)
Enterprise Value = 3.92b USD (5.37b + Debt 989.8m - CCE 2.44b)
Interest Coverage Ratio = unknown (Ebit TTM -565.2m / Interest Expense TTM 0.0)
EV/FCF = -8.13x (Enterprise Value 3.92b / FCF TTM -482.1m)
FCF Yield = -12.30% (FCF TTM -482.1m / Enterprise Value 3.92b)
FCF Margin = -11.7k% (FCF TTM -482.1m / Revenue TTM 4.10m)
Net Margin = -13.9k% (Net Income TTM -568.5m / Revenue TTM 4.10m)
Gross Margin = unknown ((Revenue TTM 4.10m - Cost of Revenue TTM 224.1m) / Revenue TTM)
Tobins Q-Ratio = 1.44 (Enterprise Value 3.92b / Total Assets 2.73b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 989.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -446.5m (EBIT -565.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.33 (Total Current Assets 2.45b / Total Current Liabilities 149.9m)
Debt / Equity = 0.55 (Debt 989.8m / totalStockholderEquity, last quarter 1.81b)
Debt / EBITDA = 2.66 (negative EBITDA) (Net Debt -1.45b / EBITDA -546.2m)
Debt / FCF = 3.01 (negative FCF - burning cash) (Net Debt -1.45b / FCF TTM -482.1m)
Total Stockholder Equity = 1.84b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.24% (Net Income -568.5m / Total Assets 2.73b)
RoE = -30.88% (Net Income TTM -568.5m / Total Stockholder Equity 1.84b)
RoCE = -23.29% (EBIT -565.2m / Capital Employed (Equity 1.84b + L.T.Debt 585.5m))
RoIC = -17.12% (negative operating profit) (NOPAT -446.5m / Invested Capital 2.61b)
WACC = 10.34% (E(5.37b)/V(6.36b) * Re(12.25%) + D(989.8m)/V(6.36b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 7.68%
[DCF] Fair Price = unknown (Cash Flow -482.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.15 | # QB: 0
Revenue Correlation: -87.63 | Revenue CAGR: -78.10% | SUE: -0.22 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.19 | Chg30d=-0.63% | Revisions=+25% | Analysts=20
EPS next Quarter (2026-09-30): EPS=-1.18 | Chg30d=+0.15% | Revisions=+15% | Analysts=20
EPS current Year (2026-12-31): EPS=-4.82 | Chg30d=-0.64% | Revisions=+5% | GrowthEPS=+25.5% | GrowthRev=+934.7%
EPS next Year (2027-12-31): EPS=-3.83 | Chg30d=+4.24% | Revisions=+17% | GrowthEPS=+20.5% | GrowthRev=+299.5%
[Analyst] Revisions Ratio: +17% (up=40, down=28)